Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

TAF

Aliases
GS-7340, TAF Placebo, Vemlidy®
Name
VEMLIDY
INN Name
tenofovir alafenamide
FDA Approved
Yes

8 clinical trials

1 organization

6 indications

1 document

Indication
Hepatitis B
Indication
Chronic
Indication
Chronic Hepatitis B
Indication
Hepatitis Delta Virus Infection
Indication
HIV-1 infection
Indication
Chronic HBV Infections
Clinical trial
A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection
Status: Terminated, Estimated PCD: 2021-12-29
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B
Status: Completed, Estimated PCD: 2015-09-30
Clinical trial
A Multicenter, Randomized, Controlled, Open-label Phase IIb Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B
Status: Completed, Estimated PCD: 2015-11-16
Clinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B
Status: Completed, Estimated PCD: 2017-02-24
Clinical trial
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1b, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Treatment With JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, HBeAg-negative Participants With Chronic Hepatitis B Virus Infection
Status: Active (not recruiting), Estimated PCD: 2023-07-31
Document
DailyMed Label: VEMLIDY
Organization
Gilead Sciences, Inc.